German biotech company CureVac, which is developing a potential COVID-19 vaccine, has secured a 75 million euro ($85 million) loan from the European Investment Bank to boost its manufacturing capacity.

The company, which is planning an initial public offering in the United States this month, said on Monday the loan will help it invest in its so-called messenger RNA approach technology and help it speed up construction of a fourth production site at its headquarters in Tuebingen, Germany. Source: Reuters 6/7/2020